

CITATION REPORT

List of articles citing

Aprepitant and fosaprepitant: a 10-year review of efficacy and safety

DOI: 10.1634/theoncologist.2014-0229
Oncologist, 2015, 20, 450-8.

Source: <https://exaly.com/paper-pdf/61975905/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
88	Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1127-33	3.5	12
87	Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron. <i>Therapeutics and Clinical Risk Management</i> , 2016 , 12, 917-25	2.9	20
86	Inhibition of tachykinin NK receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells. <i>European Journal of Pharmacology</i> , 2016 , 791, 274-283	5.3	28
85	Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 396-406	5.4	13
84	Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. <i>New England Journal of Medicine</i> , 2016 , 375, 134-42	59.2	217
83	The safety and efficacy of aprepitant in combination with other antiemetic agents for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric patients. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016 , 1, 189-195		2
82	Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance). <i>Supportive Care in Cancer</i> , 2016 , 24, 2661-7	3.9	18
81	Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 425-31	4.8	23
80	Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting. <i>Future Oncology</i> , 2016 , 12, 871-9	3.6	2
79	Management of Chemotherapy-Induced Nausea and Vomiting. 2016 ,		3
78	A Randomized Controlled Pilot Study Comparing the Impact of Aprepitant and Fosaprepitant on Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecologic Cancer. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 389-93	3.5	7
77	Progress in chemoradiotherapy-induced nausea and vomiting. <i>Lancet Oncology, The</i> , 2016 , 17, 412-413	21.7	1
76	The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 343-56	4.1	22
75	Treatment of nausea with innovative antiemetics. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017 , 2, 109-121		1
74	Cancer patients at high risk for chemotherapy-induced nausea and vomiting [Prediction assessments/tools. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017 , 2, 103-108		
73	Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. <i>Paediatric Drugs</i> , 2017 , 19, 213-222	4.2	16
72	Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 697-710	4.1	6

71	Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia. <i>Current Problems in Cancer</i> , 2017 , 41, 419-425	2.3	2
70	Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis. <i>Journal of Neuroinflammation</i> , 2017 , 14, 37	10.1	9
69	Rolapitant in the Treatment of Nausea and Vomiting Associated With Chemotherapy. <i>Clinical Medicine Insights Therapeutics</i> , 2017 , 9, 1179559X1771910	0	
68	The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders. <i>Frontiers in Cellular Neuroscience</i> , 2016 , 10, 296	6.1	54
67	A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis. <i>BioMed Research International</i> , 2017 , 2017, 5703528	3	6
66	[Vomiting]. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2017 , 70, 283-287	0.6	1
65	Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV). <i>Drug Design, Development and Therapy</i> , 2017 , 11, 947-954	4.4	3
64	Overview of the neurokinin-1 receptor antagonists. <i>Biotarget</i> , 2017 , 1, 8-8	0.7	
63	A Straightforward Deracemization of sec-Alcohols Combining Organocatalytic Oxidation and Biocatalytic Reduction. <i>European Journal of Organic Chemistry</i> , 2018 , 2018, 3031-3035	3.2	24
62	A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). <i>Annals of Oncology</i> , 2018 , 29, 452-458	10.3	34
61	Systemic hypersensitivity to fosaprepitant - A report of two cases. <i>Journal of Oncology Pharmacy Practice</i> , 2018 , 24, 76-78	1.7	3
60	Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting. <i>Current Problems in Cancer</i> , 2018 , 42, 241-255	2.3	6
59	Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. <i>OncoTargets and Therapy</i> , 2018 , 11, 6459-6478	4.4	14
58	Cross-Dehydrogenative Coupling Reactions Between P(O)-H and X-H (X = S, N, O, P) Bonds. <i>Topics in Current Chemistry</i> , 2018 , 376, 23	7.2	49
57	Safety of Polysorbate 80 in the Oncology Setting. <i>Advances in Therapy</i> , 2018 , 35, 754-767	4.1	76
56	Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 429-435	4.4	20
55	Decarboxylative cross-coupling reactions for P(O)-C bond formation.. <i>RSC Advances</i> , 2018 , 8, 26383-26398	9.7	35
54	Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects. <i>Future Oncology</i> , 2018 , 14, 2849-2859	3.6	15

53	A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2019 , 25, 1336-1342	1.7	
52	Pharmacokinetics and Pharmacology of Drugs Used in Children. 2019 , 100-176.e45		3
51	The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 1127-1132	4.1	1
50	Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database. <i>Cancer Medicine</i> , 2019 , 8, 6243-6249	4.8	2
49	Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 3439-3451	4.4	3
48	[Supportive therapy and management of side effects in dermatology]. <i>Hautarzt</i> , 2019 , 70, 975-988	1.1	
47	Evaluation of Dissolution Enhancement of Aprepitant Drug in Ternary Pharmaceutical Solid Dispersions with Soluplus [®] and Poloxamer 188 Prepared by Melt Mixing. <i>Sci</i> , 2019 , 1, 48	0.7	4
46	The translatability of pain across species. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019 , 374, 20190286	5.8	20
45	Aprepitant Drug in Ternary Pharmaceutical Solid Dispersions with Soluplus [®] and Poloxamer 188 Prepared by Melt Mixing. <i>Sci</i> , 2019 , 1, 29	0.7	5
44	Interaction of neurotransmitters and neurochemicals with lymphocytes. <i>Journal of Neuroimmunology</i> , 2019 , 332, 99-111	3.5	32
43	Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study. <i>BMC Cancer</i> , 2019 , 19, 1118	4.8	1
42	Perioperative Administration of Emend (Aprepitant) at a Tertiary Care Children's Hospital: A 12-Month Survey. <i>Clinical Pharmacology: Advances and Applications</i> , 2019 , 11, 155-160	1.5	3
41	HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis. <i>Future Oncology</i> , 2019 , 15, 241-255	3.6	3
40	Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese". <i>Cancer Medicine</i> , 2020 , 9, 170-178	4.8	1
39	Antiemetic Prophylaxis with Fosaprepitant and 5-HT-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 3915-3927	4.4	0
38	Neurokinin-1 receptor antagonists for postoperative nausea and vomiting: a systematic review and meta-analysis. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2020 , 70, 508-519	0.2	
37	[Neurokinin-1 receptor antagonists for postoperative nausea and vomiting: a systematic review and meta-analysis]. <i>Revista Brasileira De Anestesiologia</i> , 2020 , 70, 508-519	0.8	5
36	Asymmetric Synthesis of Merck's Potent hNK Antagonist and Its Stereoisomers via Tandem Acylation/[3,3]-Rearrangement of 1,2-Oxazine -Oxides. <i>Journal of Organic Chemistry</i> , 2020 , 85, 11060-11071	4.2	3

35	Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. <i>Future Oncology</i> , 2020 , 16, 1863-1872	3.6	4
34	Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA). <i>Core Evidence</i> , 2020 , 15, 21-29	4.9	2
33	One-pot strategy: A highly economical tool in organic synthesis and medicinal chemistry. 2020 , 353-425		5
32	Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 1089-1100	4.9	1
31	Stereoselective synthesis of the key intermediate of ticagrelor and its diverse analogs using a new alcohol dehydrogenase from <i>Rhodococcus kyotonensis</i> . <i>Process Biochemistry</i> , 2020 , 92, 232-243	4.8	2
30	Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial. <i>Chest</i> , 2020 , 157, 1647-1655	5.7	7
29	Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR). <i>Bioorganic Chemistry</i> , 2020 , 96, 103578	5.1	41
28	Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 1219-1226	4.4	3
27	Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT ₃ RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. <i>ESMO Open</i> , 2020 , 5,	6	13
26	Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin. <i>Therapeutics and Clinical Risk Management</i> , 2021 , 17, 73-77	2.9	
25	Recent trends in the direct oxyphosphorylation of C-C multiple bonds.. <i>RSC Advances</i> , 2020 , 11, 470-483	3.7	12
24	Modulating Ocular Surface Pain Through Neurokinin-1 Receptor Blockade. 2021 , 62, 26		8
23	Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. <i>JAMA Network Open</i> , 2021 , 4, e215250	10.4	2
22	Olanzapine Administration Reduces Chemotherapy-Induced Nausea Behavior in Rats. <i>Biological Research for Nursing</i> , 2021 , 23, 584-595	2.6	
21	Long-Term Daily Administration of Aprepitant for the Management of Intractable Nausea and Vomiting in Children With Life-Limiting Conditions: A Case Series. <i>Journal of Pain and Symptom Management</i> , 2021 , 62, e225-e231	4.8	0
20	The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 705866	5.3	0
19	Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review. <i>Current Cancer Drug Targets</i> , 2019 , 19, 765-781	2.8	1
18	Efficacy and Safety of Neurokinin-1 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting: Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016 , 17, 1661-75	1.7	17

17	Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome. <i>Cureus</i> , 2019 , 11, e4825	1.2	7
16	Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. 2016 , 107-120		2
15	Chemotherapy Induced Nausea and Vomiting. 2019 , 1007-1045		
14	Importance des interactions médicamenteuses nfastes chez le patient oncologique : comparaison de programmes de dfection informatiss. <i>Douleur Et Analgesie</i> , 2019 , 32, 21-36	0.2	
13	Infusion Site Reactions: Classification in the Setting of Fosaprepitant Administration With Chemotherapy. <i>Clinical Journal of Oncology Nursing</i> , 2020 , 24, E79-E84	1.1	
12	Effect of increase in duration of aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving combination of anthracycline/cyclophosphamide chemotherapy: A randomized, crossover, clinical trial. <i>Advanced Biomedical Research</i> , 2015 , 4, 238	1.2	1
11	Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest through PI3K/Akt/NF-B Axis in Cancer Stem-Like Esophageal Squamous Cell Carcinoma Spheres.. <i>BioMed Research International</i> , 2021 , 2021, 8808214	3	5
10	Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.. <i>Cancers</i> , 2022 , 14,	6.6	0
9	A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients.. <i>Supportive Care in Cancer</i> , 2022 ,	3.9	0
8	Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting.. <i>Future Oncology</i> , 2022 ,	3.6	0
7	Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial. <i>EClinicalMedicine</i> , 2022 , 49, 101480	11.3	
6	Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis. 2022 ,		
5	Commentary on Chemical transmission of nerve impulses by Zñon M. Bacq. 2023 , 1-7		0
4	Transition metal-free electrochemical fluorotrifluoromethylation of Styrenes.		0
3	Drugs Acting on the Brain. 2022 , 573-584		0
2	Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation.		0
1	Preparation and in vivo evaluation of an intravenous emulsion loaded with an aprepitant-phospholipid complex. 2023 , 30,		0